Leerink Partnrs Issues Pessimistic Outlook for TNYA Earnings

Key Points

• Leerink Partners has revised its FY2025 earnings estimate for Tenaya Therapeutics to a loss of ($0.71) per share, slightly down from the previous estimate of ($0.70), while the consensus estimate is a loss of ($1.35) per share.
• Tenaya Therapeutics reported a quarterly loss of ($0.14) EPS, exceeding the consensus estimate of ($0.20) by $0.06.
• Despite the earnings adjustment, Tenaya Therapeutics has had a favorable reception from analysts, with a majority rating it as a "buy" and an average price target of $6.25.

Tenaya Therapeutics, Inc. (NASDAQ:TNYA - Free Report) - Equities researchers at Leerink Partnrs lowered their FY2025 earnings per share estimates for Tenaya Therapeutics in a research report issued on Wednesday, August 6th. Leerink Partnrs analyst M. Foroohar now anticipates that the company will post earnings of ($0.71) per share for the year, down from their prior estimate of ($0.70). The consensus estimate for Tenaya Therapeutics' current full-year earnings is ($1.35) per share. Leerink Partnrs also issued estimates for Tenaya Therapeutics' Q4 2025 earnings at ($0.18) EPS and FY2026 earnings at ($0.67) EPS.

Several other research analysts have also recently issued reports on TNYA. Chardan Capital reaffirmed a "buy" rating and set a $9.00 target price on shares of Tenaya Therapeutics in a research report on Thursday, August 7th. Wall Street Zen raised Tenaya Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday. Finally, HC Wainwright reissued a "buy" rating and issued a $5.00 price objective on shares of Tenaya Therapeutics in a research report on Friday, April 25th. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $6.25.

Tenaya Therapeutics Stock Performance

Shares of NASDAQ TNYA traded up $0.08 during midday trading on Monday, hitting $0.76. 2,464,804 shares of the stock traded hands, compared to its average volume of 2,755,070. The company has a market cap of $123.38 million, a PE ratio of -0.79 and a beta of 3.01. Tenaya Therapeutics has a one year low of $0.36 and a one year high of $4.01. The business has a 50 day moving average price of $0.67 and a two-hundred day moving average price of $0.66.

Tenaya Therapeutics (NASDAQ:TNYA - Get Free Report) last released its quarterly earnings data on Wednesday, August 6th. The company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.20) by $0.06.

Institutional Trading of Tenaya Therapeutics

Hedge funds have recently made changes to their positions in the company. Woodline Partners LP bought a new stake in shares of Tenaya Therapeutics during the 4th quarter valued at $28,000. Commerce Bank purchased a new position in Tenaya Therapeutics in the 4th quarter worth approximately $29,000. Mariner LLC bought a new position in Tenaya Therapeutics in the fourth quarter valued at $30,000. Ground Swell Capital LLC bought a new position in shares of Tenaya Therapeutics during the 4th quarter valued at about $32,000. Finally, Hsbc Holdings PLC bought a new position in shares of Tenaya Therapeutics during the 4th quarter valued at about $45,000. 90.54% of the stock is currently owned by institutional investors.

About Tenaya Therapeutics

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.